Title
Category
Credits
Event date
Cost
Hidradenitis Suppurativa Clinician-Patient Summit
  • LivDerm
  • TME
  • 2.00 ACPE Pharmacy
  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 ANCC
  • 2.00 Participation
$0.00
Hidradenitis suppurativa has significant impacts on patients’ quality of life, however, it remains underdiagnosed, misdiagnosed, or incorrectly treated.  Until recently, there was a scarcity of evidence about long-term management strategies and no evidence-based consensus guidelines.  The updated North American guidelines, as well as the growing armamentarium of agents in advanced clinical development, provide additional guidance for optimizing diagnosis and treatment of HS patients.  However, questions still remain about how to best individualize therapy and work as a partner with patients
AhR Agonists for Psoriasis: A Novel Mechanism for Treatment of PsO
  • LivDerm
  • TME
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 Participation
$0.00
Psoriasis is a difficult disease to manage due to a variety of factors including fluctuations in disease severity, limited treatment options, and a limited understanding of the pathogenesis of disease. Recently, the first new topical for PsO since 1997 was approved for adults with plaque PsO. This agent is a novel, steroid-free aryl hydrocarbon receptor (AhR) agonist with no restrictions for duration, location, or extent of use.
Clinical Insights into Psoriasis in Patients of Color: Bringing New Data to Light
  • LivDerm
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 Participation
$0.00
Various gaps in the management of psoriasis in patients with SOC persist due to a lack of training for dermatology practitioners. As a result, patients with SOC are often misdiagnosed, experience more severe disease, and experience more disease burden. Given the predicted increase in the SOC population over the next decades, improving the diagnosis and management of psoriasis in these patients is critical.
According to the Patient: Alopecia Areata in Adolescence
  • LivDerm
  • TME
  • 1.00 AAPA Category I CME
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 Participation
$0.00
The management of AA in adolescents presents various challenges to dermatology professionals, including identification of AA, limited effective treatment options, and high disease burden. Because hair loss has a significant physical and psychological impact on a child’s development, early diagnosis and treatment are essential. Currently there is only one systemic therapy approved for adolescents; however, there are additional therapies on the horizon with promising data.